What emerging technologies or scientific breakthroughs do you believe will most reshape biopharma in the next 10 years?
The convergence of AI is accelerating how we understand disease and develop new therapies.
As AI capabilities continue to advance, biopharma companies are exploring how these tools can be applied thoughtfully across the drug development lifecycle.
In this commentary, Arushi Narang, Senior Business Planning Manager at Samsung Biologics, brings together perspectives from across the industry on emerging scientific advances and how CDMOs are preparing to support their efficient and reliable delivery.
The article also outlines how Samsung Biologics is developing its platforms and capabilities to help enable the next generation of therapies.
The convergence of AI is accelerating how we understand disease and develop new therapies.
As AI capabilities continue to advance, biopharma companies are exploring how these tools can be applied thoughtfully across the drug development lifecycle.
In this commentary, Arushi Narang, Senior Business Planning Manager at Samsung Biologics, brings together perspectives from across the industry on emerging scientific advances and how CDMOs are preparing to support their efficient and reliable delivery.
The article also outlines how Samsung Biologics is developing its platforms and capabilities to help enable the next generation of therapies.
Share article
Related Content